With paltusotine, we’re developing a once-daily pill for acromegaly that may replace the life-disrupting process of getting an injection every month or needing to follow a strict daily schedule for short-acting octreotide. Soon entering Phase 3, a once-daily oral therapy will be a welcome development for patients and could solve for a real market need. And there’s plenty more where that came from. Read on for our latest advancements and the market opportunities they hold for investment in our focused area of endocrinology pharmaceuticals.

Events

Dec 3, 2020 from 1:00 PM to 1:45 PM EST

3rd Annual Evercore ISI HealthCONx Conference

Dec 1 - Dec 3, 2020

Piper Sandler 32nd Healthcare Conference
Click here to view the pre-recorded fire-side chat

Nov 20, 2020 at 11:00 AM EST

KOL Call: Paltusotine for the Treatment of Acromegaly
To view the webcast archive, please register here

Press Releases

November 23, 2020

Crinetics Pharmaceuticals to Participate in December Investor Conferences

Crinetics management, including Dr. Scott Struthers and Dr. Alan Krasner, will participate in the upcoming Evercore ISI 3rd Annual HealthCONx Conference and the Piper Sandler 32nd Annual Healthcare Conference in December.

November 16, 2020

Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology

Peter Trainer, MD, FRCPE, a global leader in the endocrine community and expert in diseases of the pituitary and adrenal glands, joins Crinetics as Vice President of Clinical Endocrinology. 

View All Events
View All Press Releases

Corporate Presentation

 

Dive deeper into Crinetics, the market needs we address, our pipeline and candidate drugs, clinical trials, and more.

Corporate Presentation

Investor Resources

Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Contact

Material Selections
Country

Contact

Material Selections
Country